- Thunberg leads pro-Palestinian, climate protest in Milan
- Stock markets diverge before China weekend briefing
- EU questions shopping app Temu over illegal products risk
- Han Kang's books sell out in South Korea after Nobel win
- Shanghai markets sink ahead of briefing on mixed day for Asia
- Investors, analysts eye bigger China stimulus at Saturday briefing
- Musk unveils robotaxi, pledges it 'before 2027'
- At least 11 dead in Florida but Hurricane Milton not as bad as feared
- Asian markets mixed after Wall St drop, Shanghai dips before briefing
- Automaker Stellantis says CEO will retire in 2026
- Musk's promised robotaxi unveil delayed
- On US coast, wind power foes embrace 'Save the Whales' argument
- At least 10 dead in Florida after Hurricane Milton spawns tornadoes
- Internet Archive reels from 'catastrophic' cyberattack, data breach
- Wall Street stocks retreat from records on US inflation data
- Israel strikes central Beirut, killing 22
- Solar storm could impact US hurricane recovery efforts: agency
- Delta eyes Election Day travel pullback as profits climb
- Florida battered by hurricane, floods but spared 'worst-case scenario'
- UK's William and Kate in first joint public engagement since cancer treatment
- Over 200 women in legal talks with Harrods over Fayed abuse claims
- A very stiff breeze: BBC says sorry for 20,000 kph wind forecast
- Musk finally unveiling his long-promised robotaxi
- London's Frieze art fair goes potty for ceramics
- US, Europe stocks fall on US inflation data
- US consumer inflation eases to 2.4% in September
- Hurricane Milton tornadoes kill four in Florida amid rescue efforts
- South Korea's Han Kang wins literature Nobel
- Ikea posts fall in annual sales after lowering prices
- Stock markets diverge, oil gains after China rebounds
- World can't 'waste time' trading climate change blame: COP29 hosts
- South Korean same-sex couples make push for marriage equality
- Mumbai declares day of mourning for Indian industrialist Ratan Tata
- 7-Eleven owner restructures to fight takeover
- Sri Lanka recovering faster than expected: World Bank
- Hong Kong, Shanghai rally as most markets track Wall St record
- Uniqlo owner reports record annual earnings
- Hong Kong, Shanghai rally as markets track Wall St record
- Indonesia biomass drive threatens key forests: report
- Mumbai mourns Indian industrialist Ratan Tata
- China opens $71 bn 'swap facility' to boost markets
- Asian markets track Wall St record as Hong Kong, Shanghai stabilise
- 'Denying my potential': women at Japan's top university call out gender imbalance
- China's central bank says opens up $70.6 bn in liquidity to boost market
- Youth facing unprecedented wave of violence, UN envoy warns
- 'A casino in every kitchen': Brazil's online gambling craze
- Nobel chemistry winner sees engineered proteins solving tough problems
- Discord seen as online home for renegades
- US forecasts severe solar storm starting Thursday
- Ratan Tata: Indian mogul who built a global powerhouse
Pfizer buys biotech firm Seagen for $43 billion
US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.
Pfizer is offering $229 per share in cash, and the companies expect to complete the transaction later this year or in early 2024, they said in a statement.
"Pfizer is deploying its financial resources to advance the battle against cancer," said Pfizer CEO Albert Bourla.
"Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer's position in this important space," Bourla added.
Seagen -- leading in the research, development and commercialization of cancer treatments -- is growing, with a 12 percent increase in revenue forecast this year to $2.2 billion.
- Targeting cancer -
The company, headquartered in Washington state, came to major drugmakers' attention with its work on antibody-drug conjugates (ADCs) that are "designed to preferentially kill cancer cells."
The agreement has been approved by the boards of both firms, and will be subject to regulatory and shareholder approvals.
A deal would have to pass heightened scrutiny from antitrust regulators.
The Biden administration has also been seeking to keep down drug prices.
Pfizer expects to finance the deal through $31 billion of new long-term debt and a "combination of short-term financing and existing cash."
For now, Pfizer Oncology has a portfolio of 24 approved innovative cancer medicines that generated $12.1 billion in 2022, it said.
The deal with Seagen would double Pfizer's early-stage oncology clinical pipeline, the pharmaceutical firm added.
"The addition of Seagen's world-leading ADC technology will position us at the forefront of innovative cancer care," said Chris Boshoff, Pfizer's chief development officer of oncology and rare disease.
Seagen CEO David Epstein added that "the proposed combination with Pfizer is the right next step for Seagen to further its strategy."
According to reports, Pfizer competitor Merck was in talks with Seagen previously but these did not go through.
Pfizer expects that Seagen may contribute more than $10 billion in risk-adjusted revenues in 2030, "with potential significant growth beyond 2030," the company said.
Seagen's portfolio includes three products with ADCs, including Padcev, which is used for the treatment of urothelial cancer.
The US Food and Drug Administration is looking into combining Padcev with Merck's Keytruda in treating patients with advanced bladder cancer who are not eligible for chemotherapy.
O.Hansen--CPN